A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates

Coxsackievirus B (CVB) enteroviruses are common human pathogens known to cause severe diseases including myocarditis, chronic dilated cardiomyopathy, and aseptic meningitis. CVBs are also hypothesized to be a causal factor in type 1 diabetes. Vaccines against CVBs are not currently available, and he...

Full description

Saved in:

Bibliographic Details
Published in:	Science advances Vol. 6; no. 19; p. eaaz2433
Main Authors:	Stone, V M, Hankaniemi, M M, Laitinen, O H, Sioofy-Khojine, A B, Lin, A, Diaz Lozano, I M, Mazur, M A, Marjomäki, V, Loré, K, Hyöty, H, Hytönen, V P, Flodström-Tullberg, M
Format:	Journal Article
Language:	English
Published:	United States American Association for the Advancement of Science 01-05-2020
Subjects:	Animals Coxsackievirus Infections - prevention & control Enterovirus B, Human Health and Medicine Immunology Medicin och hälsovetenskap Mice Myocarditis Primates SciAdv r-articles Vaccines, Combined Virology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Coxsackievirus B (CVB) enteroviruses are common human pathogens known to cause severe diseases including myocarditis, chronic dilated cardiomyopathy, and aseptic meningitis. CVBs are also hypothesized to be a causal factor in type 1 diabetes. Vaccines against CVBs are not currently available, and here we describe the generation and preclinical testing of a novel hexavalent vaccine targeting the six known CVB serotypes. We show that the vaccine has an excellent safety profile in murine models and nonhuman primates and that it induces strong neutralizing antibody responses to the six serotypes in both species without an adjuvant. We also demonstrate that the vaccine provides immunity against acute CVB infections in mice, including CVB infections known to cause virus-induced myocarditis. In addition, it blocks CVB-induced diabetes in a genetically permissive mouse model. Our preclinical proof-of-concept studies demonstrate the successful generation of a promising hexavalent CVB vaccine with high immunogenicity capable of preventing CVB-induced diseases.
Bibliography:	These authors contributed equally to this work.
ISSN:	2375-2548 2375-2548
DOI:	10.1126/sciadv.aaz2433